The Board of Directors of ICI Pakistan Limited has approved the purchase of a manufacturing facility owned by Wyeth Pakistan Limited local at SITE Karachi. According to material information sent to Pakistan Stock Exchange on Friday, it is along with the acquisition of Wyeth's products and registrations, namely Entox-P, Lederplex, Lederrif, Mucaine, Nilstat, Tri-Hemic and Wymoc and products and registeration of Pfizer Pakistan Limited, namely Citralka and Combatrin, subject to all regulatory approvals.
In this regard the Board of Directors has further authorised finalisation and execution (as necessary) of the definitive transaction documents/agreement(s) including but not limited to the Asset Purchase Agreements, the Manufacturing Supply /Packaging Agreement(s) and all ancillary documents with Wyeth/Pfizer.
Comments
Comments are closed.